Methylhexanamine or methylhexamine, commonly known as dimethylamylamine (DMAA) or 1,3-dimethylamylamine (1,3-DMAA) was invented by Eli Lilly and Company in the year 1944. It was a nasal decongestant administered through inhalation having the trade names are Geramine and Forthane. On the year 1983, Methylhexanamine was voluntarily withdrawn from the market.
There are at least five deaths that has been associated with the use of methylhexanamine-containing medications. Methylhexanamine was known to have similar compounds with geraniums, however, further studies are needed in order to prove the safety of Methylhexanamine. Since the year 2006, Methylhexanamine has been exclusively sold as a stimulant or energy-enhancing dietary supplement. Many government agencies and sports authorities banned the use of Methylhexanamine.
Methylhexanamine was introduced and was sold as a nasal decongestant by Eli Lilly and Company under the brand name Forthane on the month of April in the year 1944. On the year 1983, Eli Lilly voluntarily withdrew Methylhexanamine from the market. Pharmaceutical Industries in the 20th century has become interested in compounds in this class as nasal decongestants. This led to Methylhexanamine and 4 other compounds, namely octin, propylhexedrine, tuaminoheptane, and oenethyl to be brought in the market for that use. These compounds were later on approved for its purpose on keeping a sufficiently high blood pressure for patients under anesthesia.
After ephedrine was finally banned in the United States last 2005, Methylhexanamine was once again introduced in the year 2006 by Patrick Arnold as a dietary supplement. Similar to the combination of ephedrine and caffeine, numerous supplements that focused on fat reduction and boosting energy used Methylhexanamine in combination with other substances like caffeine. Proviant Technologies, a name held by Patrick Arnold’s company, introduced Methylhexanamine under the trademarked name Geranamine.